Nova Eye Medical (EYE) - should see 100% growth in revenue this FY on a c. $20m base due to the launch of a new best in class device into the high growth minimally invasive glaucoma surgery (MIGS) market.
Only a $38m market cap, very cheap compared to peers, assets and revenue
Gross margins of 80%, with a bit of scale this should be breakeven next year and highly profitable in 2-3 years from now
Solid management, pays themselves little compensation relative to other companies on the ASX
Loaded with cash (relative to the small current cash burn). Unlikely to need to raise capital in the future due to profitability expected soon
Exciting R&D pipeline as well for future growth sources
